What We Do

A Platform Backed By Decades of Experience

At PrimeGen, we develop cell therapies based on our proprietary scientific platform, which is backed by invaluable research that spans two decades and is reinforced by a vast portfolio of intellectual property and patents.

We’ve developed proprietary GMP-compliant protocols for cultivating and expanding multipotent and pluripotent stem cells from a variety of tissues sources in a manner that maximizes viability and potency.

We have two cell therapy models currently in the clinical trials preparation phase. Our baseline MSC therapy has multipotent abilities that are valuable to the treatment of a variety of different inflammatory diseases. This allows our operational platform to be scalable and versatile for a range of hepatic, renal, pulmonary and cardiovascular disorders. Our Prime MSC therapies employ patented priming technologies and protocols for jumpstarting and enhancing the anti-inflammatory capabilities of MSCs before patient administration. Both cell therapy models are in clinical trials for the treatment of liver cirrhosis, and are being explored for several other disease models. 

We believe the performance and efficacy of cell therapies can be further enhanced by combining them with other modern medical technologies. We are pioneering the use of a variety of treatments, such as low-level laser and pulsed electromagnetic field therapy for preparing microenvironments for cell therapy, and cell encapsulation for localizing cells to a specific site for targeted cytokine therapy.

Therapeutic Applications

PrimeGen Applications

Pipeline of Therapies

PrimeGen Global Pipeline 2021

Our pipeline of cell therapies in clinical and preclinical stages of development are focused on the treatment of inflammation, the root of most diseases. Beyond our current pipeline, we are constantly exploring unique applications for cell therapies based on our proprietary MSC priming platform. We are prioritizing R&D and our clinical candidates on disease models that have significant unmet patient need, where the disease is understood at a cellular level and where our proprietary platform has the greatest potential to improve the quality of life for people around the world.

Our pipeline is comprised of a balance of wholly owned and partnered programs. We collaborate with some of the world’s leading academic leading industry players and the partners when additional resources and therapeutic area expertise may help us bring our medicines to patients more quickly.

Where We Operate

The process employed by PrimeGen has safety built into each step and ensures the highest-quality cellular end product.

Hong Kong

PrimeGen Global HQ

Rm 10-11, 10/F, Hollywood Plaza
610 Nathan Road, Kowloon, Hong Kong

California, USA

PrimeGen US

2917 Daimler St.
Santa Ana, CA 92705

Wuxi, China

PrimeGen Wuxi

1699 Huishan Avenue

Huishan Economic Development Zone

Building No. 6, 2nd Floor

WuXi City, Jiangsu Province

Peoples Republic of China

Shenzhen, China

PrimeGen Shenzhen

Gaoxin 7th Road South

Guoxin Investment Building, Room 305

Nanshan District, Shenzhen, Guangdong